全文获取类型
收费全文 | 588125篇 |
免费 | 51152篇 |
国内免费 | 23278篇 |
专业分类
耳鼻咽喉 | 3994篇 |
儿科学 | 13753篇 |
妇产科学 | 9000篇 |
基础医学 | 98073篇 |
口腔科学 | 13082篇 |
临床医学 | 46375篇 |
内科学 | 96644篇 |
皮肤病学 | 8870篇 |
神经病学 | 48829篇 |
特种医学 | 12443篇 |
外国民族医学 | 150篇 |
外科学 | 48790篇 |
综合类 | 80962篇 |
现状与发展 | 98篇 |
一般理论 | 10篇 |
预防医学 | 34176篇 |
眼科学 | 10604篇 |
药学 | 67394篇 |
154篇 | |
中国医学 | 20335篇 |
肿瘤学 | 48819篇 |
出版年
2023年 | 7397篇 |
2022年 | 10985篇 |
2021年 | 21351篇 |
2020年 | 18581篇 |
2019年 | 20387篇 |
2018年 | 19611篇 |
2017年 | 20161篇 |
2016年 | 20232篇 |
2015年 | 22584篇 |
2014年 | 34865篇 |
2013年 | 40400篇 |
2012年 | 34471篇 |
2011年 | 39796篇 |
2010年 | 33230篇 |
2009年 | 31480篇 |
2008年 | 31942篇 |
2007年 | 30562篇 |
2006年 | 27653篇 |
2005年 | 24298篇 |
2004年 | 20521篇 |
2003年 | 17414篇 |
2002年 | 13773篇 |
2001年 | 11984篇 |
2000年 | 10233篇 |
1999年 | 8949篇 |
1998年 | 7846篇 |
1997年 | 7131篇 |
1996年 | 6313篇 |
1995年 | 5711篇 |
1994年 | 5101篇 |
1993年 | 4301篇 |
1992年 | 3762篇 |
1991年 | 3330篇 |
1990年 | 2964篇 |
1989年 | 2511篇 |
1988年 | 2147篇 |
1987年 | 1987篇 |
1986年 | 1757篇 |
1985年 | 4092篇 |
1984年 | 4970篇 |
1983年 | 3971篇 |
1982年 | 3742篇 |
1981年 | 3323篇 |
1980年 | 2818篇 |
1979年 | 2391篇 |
1978年 | 1922篇 |
1977年 | 1283篇 |
1976年 | 1665篇 |
1975年 | 1293篇 |
1974年 | 1072篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
背景 致密性骨炎(OCI)和其他疾病有时难以鉴别,探讨血清骨转换生化标志物可为OCI的鉴别诊断提供依据。 目的 探索女性OCI患者的血清骨转换生化标志物的水平变化及临床意义。 方法 回顾性选取2013年6月至2022年2月在北京积水潭医院门诊及住院诊断为OCI的61例女性患者作为观察组,年龄15~50岁,平均(33.8±6.6)岁,病程2周~15年。选择同期61例女性体检健康者作为对照组,年龄15~48岁,平均(35.6±7.6)岁。比较两组一般临床资料和血清骨转换生化标志物水平,并对血清骨转换生化标志物与病情相关指标进行相关性分析。 结果 观察组血清白蛋白(45.4±2.9)g/L低于对照组(46.5±2.8)g/L(t=2.190,P<0.05)。血清骨转换生化标志物比较结果显示,观察组血清1型胶原羧基末端肽β特殊序列(β-CTX)〔0.28(0.23,0.37)μg/L〕、N-端骨钙素(OC)〔13.1(11.2,16.2)μg/L〕、25-羟维生素D3〔25-(OH)VD3〕〔(14.1±5.1)μg/L〕低于对照组〔0.36(0.29,0.48)μg/L,15.6(13.7,17.3)μg/L,(17.5±6.6)μg/L〕(Z=-2.983、-3.255,t=3.081,P<0.05)。长病程亚组OC水平〔14.6(12.4,18.5)μg/L〕高于短病程亚组〔11.7(10.2,14.0)μg/L〕(Z=-2.407,P<0.05)。多孕亚组β-CTX〔0.25(0.22,0.32)μg/L〕、OC水平〔12.2(10.3,15.0)μg/L〕低于非多孕亚组〔0.33(0.26,0.44)μg/L、13.4(12.0,18.8)μg/L〕(Z=-2.486、-1.897,P<0.05)。相关性分析显示,观察组血清1型前胶原氨基端延长肽(tP1NP)与妊娠次数、生产次数均呈负相关(rs=-0.276、-0.298,P<0.05),OC与体质指数(BMI)、视觉模拟评分法(VAS)评分、妊娠次数均呈负相关(rs=-0.284、-0.374、-0.360,P<0.05),25-(OH)VD3水平与BMI呈正相关(rs=0.275,P<0.05)。 结论 女性OCI患者血清OC、β-CTX水平明显降低,可为鉴别其他疾病提供依据;血清OC水平可以反映OCI患者的严重程度,同时OC水平与患者妊娠次数相关;tP1NP与妊娠次数、生产次数相关。 相似文献
12.
Effect of Replacement of Wharton Acellular Jelly With FBS on the Expression of Megakaryocyte Linear Markers in Hematopoietic Stem Cells CD34+ 下载免费PDF全文
zahra Jalili Behnam Emamgolizadeh Hossein Abbaszadeh Shahla JaliliMehdi Derakhshani Mehdi YousefiMehdi TalebiKarim Shams Asenjan Ali Akabr Movassaghpour 《Asian Pacific journal of cancer prevention》2022,23(10):3281-3286
Objective: Animal environments for the growth of stem cells cause the transmission of some diseases and immune problems for the recipient. Accordingly, replacing these environments with healthy environments, at least with human resources, is essential. One of the media that can be used as an alternative to animal serums is Wharton acellular jelly (AWJ). Therefore, in this study, we intend to replace FBS with Wharton jelly and investigate its effect on the expression of megakaryocyte-related genes and markers in stem cells. Materials and Methods: In this study, cord blood-derived CD34 positive HSCs were cultured and expanded in the presence of cytokines including SCF, TPO, and FLT3-L. Then, the culture of expanded CD34 positive HSCs was performed in two groups: 1) IMDM culture medium containing 10% FBS and 100 ng / ml thrombopoietin cytokine 2) IMDM culture medium containing 10% AWJ, 100 ng / ml thrombopoietin cytokine. Finally, CD41 expressing cells were analyzed with the flow cytometry method. The genes related to megakaryocyte lineage including FLI1 and GATA2 were also evaluated using the RT-PCR technique. Results: The expression of CD41, a specific marker of megakaryocyte lineage in culture medium containing Wharton acellular jelly was increased compared to the FBS group. Additionally, the expression of GATA2 and FLI1 genes was significantly increased related to the control group. Conclusion: This study provided evidence of differentiation of CD34 positive hematopoietic stem cells from umbilical cord blood to megakaryocytes in a culture medium containing AWJ. 相似文献
13.
14.
15.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
16.
17.
18.
19.
20.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献